What is pleomorphic xanthoastrocytoma?
Pleomorphic xanthoastrocytoma (PXA) is a rare brain tumour that develops from astrocytes, star-shaped support cells of the brain. It makes up less than 1% of all astrocytomas (Shaikh et al., 2019).
It mainly affects children, teenagers and young adults, and usually grows near the surface of the brain, most often in the temporal lobe. Because of this position, the most common first symptom is seizures, sometimes for months or years before diagnosis.
The name describes how the tumour looks under the microscope:
- Pleomorphic means the cells vary greatly in shape and size
- Xantho refers to fatty (lipid-filled) cells, which look yellowish
- Astrocytoma means it arises from astrocytes
PXA was first described in 1979 as a tumour of young people with a relatively favourable outlook (Kepes, Rubinstein and Eng, 1979). The WHO classification grades PXA as CNS WHO grade 2 or, when it shows more aggressive features, grade 3 (Louis et al., 2021).
Most PXAs can be treated successfully with surgery, and many people live for decades. A large proportion of PXAs carry a BRAF V600E gene change, which can be targeted with tablet treatments if the tumour comes back.
1. Key facts at a glance
| Feature | Details |
|---|---|
| Type of tumour | Circumscribed astrocytic glioma |
| WHO grade | CNS WHO grade 2 or grade 3 |
| How common | Rare; under 1% of astrocytomas |
| Typical age | Children and young adults; median around 20 years |
| Usual location | Surface of the cerebral hemispheres, especially the temporal lobe |
| Key symptom | Seizures |
| Gene changes | BRAF V600E in about two-thirds; CDKN2A/B deletion in most |
| Main treatment | Maximal safe surgery; radiotherapy for grade 3 or recurrence; BRAF/MEK inhibitors |
| Outlook | Grade 2: about 9 in 10 alive at 5 years; grade 3: poorer |
2. Causes and genetics
The cause of PXA is not known. It is not linked to lifestyle or environmental factors and is usually not inherited.
| Gene change | How often | Why it matters |
|---|---|---|
| BRAF V600E | About 60-70% (Schindler et al., 2011) | Drives tumour growth; can be targeted with BRAF and MEK inhibitors |
| Other BRAF or MAPK pathway changes | Some tumours | Also affect the same growth pathway |
| CDKN2A/B homozygous deletion | Most tumours (around 90%) | Removes a brake on cell division; helps confirm the diagnosis |
| TERT promoter mutation | Some, especially grade 3 | May indicate more aggressive behaviour |
The combination of BRAF V600E and CDKN2A/B deletion is very typical of PXA, and specialised tests on the tumour’s DNA methylation pattern can help confirm the diagnosis.
3. How does it look
On MRI
| Feature | Description |
|---|---|
| Position | Near the surface of the brain, often in the temporal lobe; sometimes parietal or frontal |
| Typical pattern | A fluid-filled cyst with a solid nodule in its wall |
| Enhancement | The solid part lights up brightly with contrast dye |
| Meninges | Often touches the brain coverings, sometimes with a “dural tail” |
| Surrounding swelling | Usually mild |
| Spread | Rare at diagnosis; can spread through the spinal fluid in some grade 3 tumours |
The cyst-and-nodule appearance can look similar to other tumours of young people, such as ganglioglioma or pilocytic astrocytoma.
Under the microscope
| Feature | Description |
|---|---|
| Cells | Very variable in size and shape, including giant cells with several nuclei |
| Xanthomatous cells | Cells filled with fat droplets |
| Eosinophilic granular bodies | Small pink droplets typical of slow-growing gliomas |
| Reticulin network | Fine fibres wrapping around individual cells or small groups |
| Lymphocytes | Scattered immune cells |
| Grade 3 features | 5 or more mitoses per 10 high-power fields; necrosis may be present |
Despite the dramatic variation in cell shapes, PXA usually behaves far less aggressively than its appearance suggests.
Visible signs
PXA does not normally cause any outward signs. Large tumours may cause weakness or changes in speech or behaviour that others notice.
4. Symptoms
Common symptoms
- Seizures, which are the most common first symptom
- Headaches, especially if worse in the morning or when lying down
- Nausea and vomiting from raised pressure in the skull
- Changes in memory, mood or behaviour
- Speech or language difficulties, especially with temporal lobe tumours
Types of seizures
| Seizure type | What it may look like |
|---|---|
| Focal aware seizures | Odd smells or tastes, deja vu, a rising feeling in the stomach, while staying aware |
| Focal impaired awareness seizures | Staring, lip-smacking, fumbling movements, with little memory of the event |
| Focal to bilateral tonic-clonic seizures | Stiffening and jerking of the whole body, loss of consciousness |
Other symptoms depending on location
| Location | Possible symptoms |
|---|---|
| Frontal lobe | Weakness on one side, personality change |
| Parietal lobe | Numbness, difficulty with spatial awareness |
| Occipital lobe | Visual disturbances |
| Cerebellum or spinal cord (rare) | Unsteadiness, back pain, limb weakness |
When to seek medical advice
See a doctor promptly after a first seizure, or for headaches that are new, persistent or worsening, especially with vomiting or changes in vision, speech or behaviour.
Call emergency services for a seizure lasting more than 5 minutes, repeated seizures without recovery in between, or sudden severe headache with drowsiness.
5. Diagnosis
| Test | Purpose |
|---|---|
| MRI with contrast | Main scan; shows the typical cyst and nodule |
| CT scan | Often the first scan in an emergency |
| EEG | Records brain electrical activity in people with seizures |
| Surgery or biopsy | Provides tissue to confirm the diagnosis |
| Immunohistochemistry | GFAP, S100, CD34 and BRAF V600E protein |
| Molecular tests | BRAF, CDKN2A/B and DNA methylation profiling |
| MRI of the spine | For grade 3 tumours or suspected spread |
Grading
| Grade | Description |
|---|---|
| CNS WHO grade 2 | Fewer than 5 mitoses per 10 high-power fields |
| CNS WHO grade 3 | 5 or more mitoses per 10 high-power fields; previously called anaplastic PXA |
Conditions that can look similar
| Condition | How it differs |
|---|---|
| Ganglioglioma | Contains abnormal nerve cells; also often BRAF V600E but usually without CDKN2A/B deletion |
| Pilocytic astrocytoma | Usually in the cerebellum; different microscopic features |
| Glioblastoma, including epithelioid type | More aggressive; older age; extensive necrosis |
| Meningioma | Arises from the brain coverings; different stains |
| Dysembryoplastic neuroepithelial tumour (DNET) | Seizure-related tumour of young people; no pleomorphic giant cells |
6. Treatment
PXA is treated by a neuro-oncology team that includes neurosurgeons, oncologists, radiologists and specialist nurses.
Surgery
Maximal safe removal of the tumour is the most important treatment. Complete removal is linked to fewer recurrences and longer survival (Ida et al., 2015).
| Goal | Notes |
|---|---|
| Gross total resection | Removing all visible tumour, when safe |
| Preserving function | Brain mapping and awake surgery may be used near speech or movement areas |
| Seizure control | Removing the tumour often improves or stops seizures |
| Repeat surgery | Often possible if the tumour comes back |
Radiotherapy
| Situation | Approach |
|---|---|
| Grade 2, completely removed | Usually monitoring with MRI only |
| Grade 2, partly removed | Monitoring or radiotherapy, depending on risk |
| Grade 3 | Radiotherapy usually recommended after surgery |
| Recurrence | Further surgery and/or radiotherapy |
In young children, radiotherapy is used cautiously because of its effects on the developing brain.
Targeted therapy
For tumours with BRAF V600E, tablets that block the BRAF growth signal can shrink the tumour:
| Treatment | Notes |
|---|---|
| Dabrafenib plus trametinib | BRAF plus MEK inhibitor; responses seen in BRAF V600E gliomas, including PXA (Wen et al., 2022) |
| Vemurafenib (with or without cobimetinib) | Responses in PXA in the VE-BASKET study (Kaley et al., 2018) |
| Other options | Encorafenib with binimetinib; clinical trials |
These drugs are mainly used for recurrent or progressive tumours, or tumours that cannot be removed.
Chemotherapy
Chemotherapy, such as temozolomide, has been used, but its benefit in PXA is uncertain.
Seizure management
| Treatment | Notes |
|---|---|
| Anti-seizure medicines | Such as levetiracetam or lamotrigine |
| After surgery | Medicines may be reduced or stopped gradually if seizures stop |
| Driving | Rules after seizures vary by country; ask your team |
What treatment involves day to day
| Part of treatment | What to expect |
|---|---|
| Before surgery | MRI, sometimes functional MRI or brain mapping, blood tests and an anaesthetic check |
| Surgery | Usually a few hours; sometimes awake surgery for tumours near speech areas |
| After surgery | One night in intensive or high-dependency care, then a few days on the ward |
| Steroids | Dexamethasone may be given for a short time to reduce brain swelling |
| Recovery at home | Tiredness for several weeks; no driving until cleared |
| Radiotherapy (if needed) | Daily sessions on weekdays for about 6 weeks, with a fitted mask to keep the head still |
| Targeted tablets (if needed) | Taken at home every day, with regular blood tests, heart and eye checks |
Most people can return to school or work within weeks to a few months after surgery alone.
PXA in children
PXA is one of the brain tumours seen most often in older children and teenagers with seizures. Treatment follows the same principles as in adults, with a strong emphasis on complete surgery and avoiding or delaying radiotherapy where possible, to protect the developing brain.
Children are treated at a children’s neuro-oncology centre, and BRAF and MEK inhibitors are increasingly used for children whose tumours come back or cannot be removed. Support with learning, behaviour and seizures at school is an important part of care.
Side effects
| Treatment | Possible side effects |
|---|---|
| Brain surgery | Swelling, weakness, speech problems or seizures, usually temporary |
| Radiotherapy | Tiredness, hair loss in the treated area, later memory and concentration problems |
| BRAF and MEK inhibitors | Fever, rash, tiredness, joint pain, changes in heart and eye function |
| Anti-seizure medicines | Drowsiness, mood changes, dizziness |
7. Outlook (prognosis)
| Group | Approximate outlook |
|---|---|
| Grade 2 PXA | About 90% alive at 5 years; many live for decades (Ida et al., 2015) |
| Grade 3 PXA | About half to 6 in 10 alive at 5 years |
| Complete removal | Better outcome |
| Recurrence | Occurs in a minority; may happen years later and sometimes at a higher grade |
Some PXAs can transform into a more aggressive tumour over time, so regular MRI follow-up is important.
In the long-term Mayo Clinic series, the extent of surgery and the tumour grade were the factors most strongly linked with survival. Recurrent tumours can often be treated again with surgery, radiotherapy or targeted tablets, and many people with a recurrence still live for many years.
8. Follow-up
| Follow-up | Purpose |
|---|---|
| MRI scans | Every 3-6 months at first, then yearly if stable |
| Neurology review | Seizure control and medication |
| Neuropsychology | Memory, learning and concentration, especially in children |
| Endocrine checks | After radiotherapy near hormone-producing areas |
| School or work support | Help with returning to education or employment |
9. Living with PXA
- Take anti-seizure medicines exactly as prescribed
- Keep a seizure diary to share with your team
- Get enough sleep and avoid alcohol excess, which can trigger seizures
- Ask about driving rules after seizures or surgery
- Use school support: teachers can adjust learning plans for children
- Seek support from brain tumour charities and peer groups
10. Frequently asked questions
| Question | Answer |
|---|---|
| Is PXA cancer? | It is a primary brain tumour; grade 2 PXA usually grows slowly, while grade 3 behaves more aggressively |
| Will the seizures stop after surgery? | Often they improve or stop, especially after complete removal |
| Can it come back? | Yes, sometimes years later, so long-term MRI follow-up is needed |
| What does BRAF V600E mean for me? | Targeted tablets may be an option if the tumour returns or grows |
| Is it inherited? | Usually not |
| Will I be able to drive again? | Usually, once you have been seizure-free for the period required by your country’s rules |
| Can children lead normal lives? | Many do, with support for any learning or seizure problems |
11. Questions to ask your care team
- Is my tumour grade 2 or grade 3?
- Was it completely removed?
- Does it have a BRAF V600E change?
- Do I need radiotherapy now, or can we monitor with MRI?
- How long will I need anti-seizure medicines?
- How often will I need MRI scans?
Resources
- Ida, C.M. et al. (2015) ‘Pleomorphic xanthoastrocytoma: natural history and long-term follow-up’, Brain Pathology, 25(5), pp. 575-586.
- Kaley, T. et al. (2018) ‘BRAF inhibition in BRAF(V600)-mutant gliomas: results from the VE-BASKET study’, Journal of Clinical Oncology, 36(35), pp. 3477-3484.
- Kepes, J.J., Rubinstein, L.J. and Eng, L.F. (1979) ‘Pleomorphic xanthoastrocytoma: a distinctive meningocerebral glioma of young subjects with relatively favorable prognosis. A study of 12 cases’, Cancer, 44(5), pp. 1839-1852.
- Louis, D.N. et al. (2021) ‘The 2021 WHO classification of tumors of the central nervous system: a summary’, Neuro-Oncology, 23(8), pp. 1231-1251.
- Schindler, G. et al. (2011) ‘Analysis of BRAF V600E mutation in 1,320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma’, Acta Neuropathologica, 121(3), pp. 397-405.
- Shaikh, N. et al. (2019) ‘Pleomorphic xanthoastrocytoma: a brief review’, CNS Oncology, 8(3), CNS39.
- Wen, P.Y. et al. (2022) ‘Dabrafenib plus trametinib in patients with BRAF(V600E)-mutant low-grade and high-grade glioma (ROAR): a multicentre, open-label, single-arm, phase 2, basket trial’, The Lancet Oncology, 23(1), pp. 53-64.
- National Cancer Institute (2026) Pleomorphic Xanthoastrocytoma (PXA) and Other BRAF-Altered Tumors: Diagnosis and Treatment. Available at: https://www.cancer.gov/rare-brain-spine-tumor/tumors/pleomorphic-xanthroastrocytoma (Accessed: October 2026).
Prepared by the editorial team, October 2026.